Maintenance therapy with certolizumab pegol for Crohn's disease.

By Stefan Schreiber, M. Khaliq-Kareemi, I. Lawrance, O. Thomsen, S. Hanauer, J. McColm, R. Bloomfield, W. Sandborn. New England Journal of Medicine, 2007

1,049 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/b481b032f8d54fe8d49f9b6449ae6765c79bc951

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Colombel
2. A. Chan
3. Stefan Schreiber
4. P. Carter

In Immunology

1. Stefan Schreiber
2. P. Carter

In Rheumatology

1. J. Colombel
2. Stefan Schreiber

Citations in the corpus

• Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. (2012, background): “0) Patients with a CDEIS of 0, n (%) 39 (34) Patients with a CDEIS of 0–3, n (%) 50 (43) Patients with a CDEIS 3, n (%) 26 (23) Patients with remaining ulcers, n (%) 39 (34) Patients with remaining deep ulcers, n (%) 4 (3)”
• TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. (2014, background): “It has demonstrated efficacy, with or without co-immunosuppressant agents, for patients with moderate-to-severe Crohn’s disease [172,173].”
• Therapeutic antibodies for autoimmunity and inflammation (2010, background): “However, the therapeutic success of certolizumab pegol and the preliminary clinical efficacy of golimumab in Crohn's disease, agents that do not induce apoptosis of activated T cells or macrophages, suggest that other mechanisms probably contribute to the efficacy of TNF-specific agents in Crohn's d”
• Certolizumab pegol for the treatment of Crohn’s disease (2011, methodology): “Reprinted with permission from the Massachusetts Medical Society [Schreiber et al. 2007], copyright ! 2007.”